Septerna, Inc.
NASDAQ:SEPNBiotechnology
-$0.73 today
- Market cap
- $1.88B
- Beta
- 2.38
- P/E (TTM)
- -43.6
- EPS (TTM)
- -$0.81
Volume 0.30M
Average 0.32M
SEPN Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Septerna, Inc.NASDAQ: SEPN
Retained Earnings · Q3 FY2026 · quarter ended Sep 2026
Retained earnings remains negative
Q3 FY2026 retained earnings was -$215.51M, compared with -$156.52M a year earlier.
Context
- Retained earnings amounted to 34.8% of total assets at the end of Q3 FY2026, up 9.0 pp from a year earlier.
- Retained earnings grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -37.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (167.25M) USD
- Year-over-year change
- -41.3%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (167.25M) | -41.3% |
| FY2024 | 2024-12-31 | (118.37M) | -154.2% |
| FY2023 | 2023-12-31 | (46.58M) | +8.2% |
| FY2022 | 2022-12-31 | (50.76M) | — |
Retained Earnings vs competitors
How SEPN compares with its peers on the latest reported figures
- SEPN's Sep 2026 retained earnings of -$215.51M is the highest of the 7 companies compared; the peer median is -$487.61M.
- Its year-over-year change of -37.7% is the 4th highest of 6, against a peer median of -31.3%.
- Retained earnings amounts to 34.8% of total assets for SEPN, versus a peer median of 95.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
SEPNSepterna, Inc. | Sep 2026 | -$215.51M | -37.7% | — | 34.8% |
| Mar 2026 | -$302.56M | +0.7% | — | 306.2% | |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | -$347.51M | -71.7% | — | 69.4% |
| Mar 2026 | -$461.46M | -10.8% | — | 994.9% | |
| Mar 2026 | -$513.76M | -31.3% | — | 122.4% | |
KLRAKailera Therapeutics, Inc. | Jun 2026 | -$558.84M | — | — | 46.1% |
| Jun 2026 | -$652.43M | -49.1% | — | 45.8% | |
| Peer median (excluding SEPN) | -$487.61M | -31.3% | — | 95.9% | |
Competitors are the stored peer set for SEPN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Septerna, Inc.
NASDAQ:SEPN
Intrinsic Alpha fair value
Locked
Current Price
$39.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.